Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Emily Chan

Showing results (191-200 of 263) with videos related to

Pageof 27
Sort By:
Cancer Research|March 30, 2013
A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growthTed Lau, Emily Chan, Marinella Callow, et al.
The New England Journal of Medicine|March 14, 2008
Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactoseChristine H Chung, Beloo Mirakhur, Emily Chan, et al.
The Oncologist|January 21, 2016
Phase II Study of Olaparib (AZD-2281) After Standard Systemic Therapies for Disseminated Colorectal CancerLawrence Leichman, Susan Groshen, Bert H O'Neil, et al.
Pharmacogenetics and Genomics|December 15, 2015
Association between DPYD c.1129-5923 C>G/hapB3 and severe toxicity to 5-fluorouracil-based chemotherapy in stage III colon cancer patients: NCCTG N0147 (Alliance)Adam M Lee, Qian Shi, Steven R Alberts, et al.
Molecular Cancer Therapeutics|November 8, 2014
Modeling targeted inhibition of MEK and PI3 kinase in human pancreatic cancerMelissa R Junttila, Vidusha Devasthali, Jason H Cheng, et al.
Cancer Research|August 19, 2017
Therapeutic Targeting of the CBP/p300 Bromodomain Blocks the Growth of Castration-Resistant Prostate CancerLingyan Jin, Jesse Garcia, Emily Chan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 11, 2025
Overall Survival Analysis of the Phase III CodeBreaK 300 Study of Sotorasib Plus Panitumumab Versus Investigator's Choice in Chemorefractory <i>KRAS</i> G12C Colorectal CancerFilippo Pietrantonio, Lisa Salvatore, Taito Esaki, et al.
Health Promotion International|December 9, 2020
Communication strategies and media discourses in the age of COVID-19: an urgent need for actionMélissa Généreux, Marc D David, Tracey O'Sullivan, et al.
The Lancet. Oncology|October 14, 2016
Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trialPadmanee Sharma, Margaret K Callahan, Petri Bono, et al.
Histopathology|October 16, 2025
In reply to: 'Prostate cancer with favorable histology is not synonymous with prostate cancer indolence'Jesse K McKenney, James D Brooks, Jane K Nguyen, et al.
Pageof 27

Showing results (191-200 of 263) with videos related to

Sort By:
Pageof 27
Cancer Research|March 30, 2013
A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growthTed Lau, Emily Chan, Marinella Callow, et al.
The New England Journal of Medicine|March 14, 2008
Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactoseChristine H Chung, Beloo Mirakhur, Emily Chan, et al.
The Oncologist|January 21, 2016
Phase II Study of Olaparib (AZD-2281) After Standard Systemic Therapies for Disseminated Colorectal CancerLawrence Leichman, Susan Groshen, Bert H O'Neil, et al.
Pharmacogenetics and Genomics|December 15, 2015
Association between DPYD c.1129-5923 C>G/hapB3 and severe toxicity to 5-fluorouracil-based chemotherapy in stage III colon cancer patients: NCCTG N0147 (Alliance)Adam M Lee, Qian Shi, Steven R Alberts, et al.
Molecular Cancer Therapeutics|November 8, 2014
Modeling targeted inhibition of MEK and PI3 kinase in human pancreatic cancerMelissa R Junttila, Vidusha Devasthali, Jason H Cheng, et al.
Cancer Research|August 19, 2017
Therapeutic Targeting of the CBP/p300 Bromodomain Blocks the Growth of Castration-Resistant Prostate CancerLingyan Jin, Jesse Garcia, Emily Chan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 11, 2025
Overall Survival Analysis of the Phase III CodeBreaK 300 Study of Sotorasib Plus Panitumumab Versus Investigator's Choice in Chemorefractory <i>KRAS</i> G12C Colorectal CancerFilippo Pietrantonio, Lisa Salvatore, Taito Esaki, et al.
Health Promotion International|December 9, 2020
Communication strategies and media discourses in the age of COVID-19: an urgent need for actionMélissa Généreux, Marc D David, Tracey O'Sullivan, et al.
The Lancet. Oncology|October 14, 2016
Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trialPadmanee Sharma, Margaret K Callahan, Petri Bono, et al.
Histopathology|October 16, 2025
In reply to: 'Prostate cancer with favorable histology is not synonymous with prostate cancer indolence'Jesse K McKenney, James D Brooks, Jane K Nguyen, et al.
Pageof 27